Nasal Vaccine Starts Trial to Protect Against Alzheimer's

Following years of preparation, scientists from Brigham and Women's Hospital are ready to start a clinical trial that will evaluate the use of an intranasal vaccine to prevent Alzheimer's disease (AD).

The candidate vaccine uses the immune modulator Protollin and works by activating monocytes in the cervical lymph nodes, which then travel to the brain and initiate the clearance of beta amyloid plaques, one of the hallmarks of AD, without creating antibodies. Protollin is developed, produced, and commercialized by I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical.